| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - Cysteamine is a radiation-protective agent that oxidizes in air to form cystamine. It can be given intravenously or orally to treat radiation sickness. The bitartrate and hydrochloride salt forms are indicated for the treatment of neuropathic cystinosis in patients 6 years old and older. [PubChem]. Cysteamine is marketed under several brand names such as Cystaran™, Procysbi, and Cystagon®. (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Lukashin BP, Grebeniuk AN: [Comparative study of the radiation-protective effectiveness of low doses of cysteamine, heparin, and naphtizine in experiments on mice] Radiats Biol Radioecol. 2001 May-Jun;41(3):310-2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11458646 # Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA: Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr. 2010 Jan;156(1):71-75.e1-3. doi: 10.1016/j.jpeds.2009.07.016. Epub . "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19775699 # FDA label. (en)
|
| http://linked.open...gy/drugbank/group
| - approved (en)
- investigational (en)
|
| http://linked.open...ugbank/indication
| - Given intravenously or orally to treat radiation sickness. The bitartrate salts (Cystagon® and Procysbi) have been used for the oral treatment of nephropathic cystinosis and cystinurea. The hydrochloride salt (Cystaran™) is indicated for the treatment of corneal cystine crystal accumulation in cystinosis patients. (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - The free thiol cysteamine depletes cystinotic leukocytes and other cells of cystine, whose accumulation is considered the cause of organ damage in cystinosis. Cysteamine cleaves the disulfide bond with cystine to produce molecules that can escape the metabolic defect in cystinosis and cystinuria. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open.../drugbank/synonym
| - Mercaptamine (en)
- Cysteamine (en)
- 2-Amino-1-ethanethiol (en)
- 2-Aminoethanethiol (en)
- MEA (en)
- Thioethanolamine (en)
- beta-Aminoethanethiol (en)
- beta-MEA (en)
- beta-Mercaptoethylamine (en)
- 2-AMINO-ethanethiol (en)
- Mercaptamina (en)
- Mercaptaminum (en)
- beta-Aminoethylthiol (en)
- β-MEA (en)
- β-aminoethylthiol (en)
|
| http://linked.open...drugbank/toxicity
| - Symptoms of overdose may include convulsions (seizures), increased thirst and unusual tiredness or weakness. (en)
|
| http://linked.open...umeOfDistribution
| - Cystagon® has a volume of distribution of 156 L. (en)
|
| http://linked.open...k/foodInteraction
| - Avoid administration of delayed release cysteamine less than 30 minutes before and within 2 hours after ingesting food due to decreased bioavailability of cysteamine. (en)
|
| http://linked.open...nk/proteinBinding
| - Cysteamine has a plasma protein binding of 52% and is mostly bound to albumin. (en)
|
| http://linked.open...ogy/drugbank/salt
| |
| http://linked.open...ynthesisReference
| - Tethuharu Okazaki, Takeo Komukai, Saburo Uchikuga, "Process for preparing cysteamine-S-substituted compounds and derivatives thereof." U.S. Patent US4371472, issued September, 1969. (en)
|
| http://linked.open...y/mesh/hasConcept
| |
| foaf:page
| |
| http://linked.open...ugbank/IUPAC-Name
| |
| http://linked.open...gy/drugbank/InChI
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...noisotopic-Weight
| |
| http://linked.open...y/drugbank/SMILES
| |
| http://linked.open.../Water-Solubility
| |
| http://linked.open...ogy/drugbank/logP
| |
| http://linked.open...ogy/drugbank/logS
| |
| http://linked.open...l/drug/hasATCCode
| |
| http://linked.open...nd-Acceptor-Count
| |
| http://linked.open...-Bond-Donor-Count
| |
| http://linked.open...drugbank/InChIKey
| |
| http://linked.open...urface-Area--PSA-
| |
| http://linked.open...nk/Polarizability
| |
| http://linked.open...bank/Refractivity
| |
| http://linked.open...atable-Bond-Count
| |
| http://linked.open...ugbank/absorption
| - Cystagon® reaches its maximum plasma concentration in about 1.4 hours. (en)
|
| http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
| http://linked.open...casRegistryNumber
| |
| http://linked.open...drugbank/category
| |
| http://linked.open...rugbank/clearance
| - The plasma clearance is about 1.2 L/min. (en)
|
| http://linked.open...gbank/containedIn
| |
| http://linked.open...k/Bioavailability
| |
| http://linked.open...bank/Ghose-Filter
| |
| http://linked.open...nk/MDDR-Like-Rule
| |
| http://linked.open...ank/Melting-Point
| |
| http://linked.open...k/Number-of-Rings
| |
| http://linked.open...siological-Charge
| |
| http://linked.open...bank/Rule-of-Five
| |
| http://linked.open...tional-IUPAC-Name
| |
| http://linked.open...strongest-acidic-
| |
| http://linked.open...-strongest-basic-
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)